Aligos Therapeutics, Inc. ( ALGS ) NASDAQ Global Select

Cena: 7.64 ( -7.33% )

Aktualizacja 06-25 17:05
NASDAQ Global Select
Branża: Biotechnology
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 68
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 69%
Ilość akcji: 78 189 248
Debiut giełdowy: 2020-10-16
WWW: https://www.aligos.com
CEO: Dr. Lawrence M. Blatt MBA, Ph.D.
Adres: One Corporate Drive
Siedziba: 94080 South San Francisco
ISIN: US01626L1052
Opis firmy:

ALIGOS Therapeutics, Inc., firma biofarmaceutyczna na etapie klinicznym, koncentruje się na opracowaniu nowych terapeutycznych w celu zaspokojenia niezaspokojonych potrzeb medycznych w chorobach wirusowych i wątroby. Jego wiodącym kandydatem na leki jest ALG-010133, polimer oligonukleotydowy hamujący transport S, który jest w fazie badań klinicznych IB w leczeniu przewlekłego zapalenia wątroby typu B (CHB); oraz ALG -000184, modulator zespołu kapsydowego, który jest w badaniach klinicznych fazy I w celu leczenia CHB. Firma opracowuje również ALG-020572, antysensowny oligonukleotyd, aby zapobiec tłumaczeniu i wydzielaniu HBSAG; i ALG-055009, agonista o małej cząsteczce Thr-ß, który znajduje się w fazie 1A/1B w leczeniu niealkoholowego zapalenia stłuszczeniowego (NASH). Ponadto opracowuje kandydata na leki siRNA, ALG-125755, a także ALG-125097 i ALG-125819, wykazało silne hamowanie uwalniania HBSAG z komórek zakażonych HBV. Zawarła umowy licencyjne i współpracujące z Luxna Biotech Co., Ltd. w celu opracowania i komercjalizacji produktów zawierających oligonukleotydy ukierunkowane na genom wirusa zapalenia wątroby typu B; Emory University, aby zapewnić technologię modulatora kapsydu wirusa wirusa wirusa B; Badania, licencjonowanie i umowa komercjalizacyjna z Katholieke Universiteit Leuven w celu opracowania inhibitorów proteazy koronawirusa; i Merck do odkrywania, badań, optymalizacji i rozwijania oligonukleotydów skierowanych przeciwko Nash. Firma została zarejestrowana w 2018 roku i ma siedzibę w South San Francisco w Kalifornii.

Wskaźniki finansowe
Kapitalizacja (USD) 46 691 390
Aktywa: 88 426 000
Cena: 7.64
Wskaźnik Altman Z-Score: -9.8
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -0.4
Ilość akcji w obrocie: 69%
Średni wolumen: 158 616
Ilość akcji 6 114 800
Wskaźniki finansowe
Przychody TTM 5 997 000
Zobowiązania: 38 330 000
Przedział 52 tyg.: 3.76 - 46.8
Piotroski F-Score: 3
Słaby (niska jakość finansowa)
EPS: -17.5
P/E branży: 26.1
Beta: 2.116
Raport okresowy: 2025-08-04
WWW: https://www.aligos.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Julian A. Symons DPHIL Executive Vice President & Chief Scientific Officer 735 515 1962
Dr. Lawrence M. Blatt MBA, Ph.D. Chief Executive Officer, President & Chairman of the Board 1 032 768 1962
Kristina Engeseth Vice President and Head of People & Culture 0 0
Dr. Sushmita M. Chanda DABT, Ph.D. Executive Vice President & Chief Development Officer 0 1967
Ms. Lesley Ann Calhoun CPA Executive Vice President & Chief Financial Officer 0 1966
Dr. David B. Smith Ph.D. Executive Vice President & Head of Chemical Operations 0 0
Dr. Tse-I Lin Ph.D. Vice President of Early Compound Development & Belgian Site Head 0 0
Wiadomości dla Aligos Therapeutics, Inc.
Tytuł Treść Źródło Aktualizacja Link
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 26,000 shares of the Company's stock (the “Inducement Grant”) to a newly hired employee on May 13, 2025 (the “Grant Date”), in connection with the commencement of employment. globenewswire.com 2025-05-16 12:00:00 Czytaj oryginał (ang.)
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025 SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands. globenewswire.com 2025-05-08 12:00:00 Czytaj oryginał (ang.)
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $2.11 per share versus the Zacks Consensus Estimate of a loss of $2.80. This compares to loss of $5.50 per share a year ago. zacks.com 2025-05-06 14:35:46 Czytaj oryginał (ang.)
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the first quarter 2025. globenewswire.com 2025-05-06 12:00:00 Czytaj oryginał (ang.)
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025 SOUTH SAN FRANCISCO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets. globenewswire.com 2025-04-29 12:30:00 Czytaj oryginał (ang.)
Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025 SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced eight abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/. globenewswire.com 2025-04-23 20:05:00 Czytaj oryginał (ang.)
LIVMARLI Now Approved in Japan for ALGS and PFIC FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--LIVMARLI Now Approved in Japan for ALGS and PFIC. businesswire.com 2025-03-27 10:30:00 Czytaj oryginał (ang.)
Aligos Therapeutics Presents Positive Data at APASL 2025 SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from three oral presentations at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2025, being held March 26 - 30, 2025 in Beijing, China. globenewswire.com 2025-03-26 10:00:00 Czytaj oryginał (ang.)
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 4,000 shares of the Company's stock (the “Inducement Grant”) to a newly hired employee on March 11, 2025 (the “Grant Date”), in connection with the commencement of employment. globenewswire.com 2025-03-14 10:00:00 Czytaj oryginał (ang.)
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $5.50 per share a year ago. zacks.com 2025-03-10 12:30:30 Czytaj oryginał (ang.)
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2024. globenewswire.com 2025-03-10 10:00:00 Czytaj oryginał (ang.)
Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025 SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's fourth quarter 2024 financial results on Monday, March 10, 2025, before the open of the U.S. financial markets. globenewswire.com 2025-03-03 10:00:00 Czytaj oryginał (ang.)
Aligos Therapeutics Announces $105 Million Private Placement Financing Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into the second half of 2026 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $105 million, before deducting placement agents' fees and other expenses. globenewswire.com 2025-02-12 09:00:00 Czytaj oryginał (ang.)
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 5,500 shares of the Company's stock (the “Inducement Grant”) to a newly hired employee on December 10, 2024 (the “Grant Date”), in connection with the commencement of employment. globenewswire.com 2024-12-13 10:00:00 Czytaj oryginał (ang.)
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024 SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from one late-breaker oral and three poster presentations at the American Association for the Study of Liver Disease's (AASLD) The Liver Meeting (TLM) 2024, being held November 15 – 19, 2024 in San Diego, CA. globenewswire.com 2024-11-19 15:30:00 Czytaj oryginał (ang.)
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.07 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to loss of $10.25 per share a year ago. zacks.com 2024-11-06 21:06:17 Czytaj oryginał (ang.)
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2024. globenewswire.com 2024-11-06 18:05:00 Czytaj oryginał (ang.)
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting . businesswire.com 2024-10-31 10:30:00 Czytaj oryginał (ang.)
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 95,000 shares of the Company's stock (the “Inducement Grants”) to newly hired employees on October 8, 2024 (the “Grant Date”), in connection with the commencement of employment. Included in the aggregate number is the grant of an option to purchase 75,000 shares to Dr. Hardean Achneck, in connection with the commencement of his role as Chief Medical Officer. globenewswire.com 2024-10-11 12:00:00 Czytaj oryginał (ang.)
Aligos Therapeutics Appoints David Perry as Vice President of Business Development SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of David Perry as Vice President of Business Development, effective immediately. globenewswire.com 2024-10-01 12:00:00 Czytaj oryginał (ang.)
Aligos Therapeutics to Present at Investor Conferences in October SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will participate at two investor conferences being webcast in October: globenewswire.com 2024-09-30 12:00:00 Czytaj oryginał (ang.)
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects. globenewswire.com 2024-09-19 12:00:00 Czytaj oryginał (ang.)
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024 SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Company will share the topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects on Thursday, September 19, 2024 prior to the market open. Following the announcement, the Company will host a conference call and webcast at 8:30am ET/5:30am PT. globenewswire.com 2024-09-18 21:00:00 Czytaj oryginał (ang.)
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 3,500 shares of the Company's stock (the “Inducement Grant”) to a newly hired employee on September 10, 2024 (the “Grant Date”), in connection with the commencement of employment. globenewswire.com 2024-09-13 12:00:00 Czytaj oryginał (ang.)
Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year? Here is how Aligos Therapeutics, Inc. (ALGS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year. zacks.com 2024-09-10 14:46:38 Czytaj oryginał (ang.)
How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14% The average of price targets set by Wall Street analysts indicates a potential upside of 648.1% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com 2024-08-21 14:55:54 Czytaj oryginał (ang.)
Aligos Therapeutics Announces Reverse Stock Split SOUTH SAN FRANCISCO, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will effect a 1-for-25 reverse stock split of its shares of common stock. The reverse stock split will become effective at 12:01 am ET on Monday, August 19, 2024. The Company's common stock is expected begin trading on the Nasdaq Capital Market under the same symbol (ALGS) on a split-adjusted basis at the market open on August 19, 2024 with the new CUSIP number 01626L 204. globenewswire.com 2024-08-15 13:00:00 Czytaj oryginał (ang.)
What Makes Aligos Therapeutics (ALGS) a New Buy Stock Aligos Therapeutics (ALGS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2024-08-09 17:01:20 Czytaj oryginał (ang.)
Aligos Therapeutics Strengthens Board with Two New Independent Directors SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) --  Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the appointment of Heather Preston, M.D. and Margarita Chavez, J.D. as Class II Independent Directors to the Board of Directors, effective August 7, 2024. Dr. Preston will join the Nominating and Corporate Governance Committee as Chair and Ms. Chavez will join the Audit Committee. globenewswire.com 2024-08-08 20:05:00 Czytaj oryginał (ang.)
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd. Amoytop to sponsor a Phase 1b exploratory clinical study evaluating the efficacy and safety of ALG-000184 in combination with PEGBING® (Mipeginterferon alfa-2b) in CHB patients globenewswire.com 2024-07-22 13:00:00 Czytaj oryginał (ang.)
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB SOUTH SAN FRANCISCO, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual KOL event featuring Mark Sulkowski, MD, Johns Hopkins University School of Medicine, to discuss the unmet need and current treatment landscape for patients with chronic hepatitis B (CHB), positive data from the Phase 1b study of ALG-000184, development plans, and the chronic suppression regulatory pathway on Thursday, July 18, 2024 at 3:00pm ET/12:00pm PT. globenewswire.com 2024-07-10 12:00:00 Czytaj oryginał (ang.)
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024 SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from six poster presentations at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy. globenewswire.com 2024-06-05 06:30:00 Czytaj oryginał (ang.)
Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now Aligos Therapeutics (ALGS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. zacks.com 2024-06-04 14:56:23 Czytaj oryginał (ang.)